This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Korsch, the global leader in tablet press technology, offering solutions for product development, scale-up, high-speed production, multi-layer, continuous manufacturing, and high-containment applications, has announced the acquisition of Medelpharm, the innovator and global leader in compaction simulator technology.
After working closely for more than a year in the context of a global strategic partnership, the acquisition leverages the companies’ combined 135-plus years of experience with small-scale, fully instrumented tablet compression equipment. The Korsch R&D product portfolio addresses and overcomes longstanding challenges, from early-stage powder characterization and formulation development, to predictive scale-up and production support. The combined Korsch-Medelpharm R&D equipment lineup includes:
- XP 1: Robust single-punch tablet press with small batch capabilities
- Styl’One Nano: Benchtop compaction simulator with integrated analytical software, for single layer formulation development
- Styl’One Evo: Advanced compaction simulator with integrated analytical software and multi-layer capability, allowing R&D at production speed
- XL 100: Small-scale rotary press for product development and clinical batch production
Covering the full spectrum of tableting technology from single-layer to five-layer, as well as core coating capabilities, the new R&D product equipment portfolio serves as a versatile complement to Korsch’s multi-layer production machinery. Notably, the Styl’One Evo offers the ability to simulate all high-speed production presses to predict product performance with minimal material quantities.
The combined R&D product line offers the latest in high-containment technology, with fully integrated dry containment (DryCon) and wash-in-place containment (WipCon®) solutions across the full range of OEB 3, OEB 4, and OEB 5 applications.